Experiences of giving oseltamivir to school children during the 2009 influenza A(H1N1) pandemic

Eurosurveillance

Volumn 15, Issue 19, 2010, Pages 7-

  Giesecke, J ^a  

^a EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR;

DISEASE ASSOCIATION; EDITORIAL; FATIGUE; HEADACHE; HUMAN; INFECTION CONTROL; INFECTION RISK; INFLUENZA A (H1N1); MEDICATION COMPLIANCE; MOOD DISORDER; NAUSEA; PANDEMIC; PROPHYLAXIS; SIDE EFFECT; SLEEP DISORDER; STOMACH PAIN;

EID: 77953282964     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: None     Document Type: Editorial

References (8)

1. Strong M, Burrows J, Stedman E, Redgrave P. Adverse drug effects following oseltamivir mass treatment and prophylaxis in a school outbreak of 2009 pandemic influenza A(H1N1) in June 2009, Sheffield, United Kingdom. Euro Surveill. 2010;15(19). pii=19565. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19565
2. Wallensten A, Oliver I, Lewis D, Harrison S. Compliance and side effects of prophylactic oseltamivir treatment in a school in South West England. Euro Surveill. 2009;14(30). pii=19285. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19285
3. Kitching A, Roche A, Balasegaram S, Heathcock R, Maguire H. Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009 - an internet-based cross-sectional survey. Euro Surveill. 2009;14(30). pii=19287. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19287
4. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese Experience with Vaccinating Schoolchildren against Influenza. N Engl J Med. 2001;344(12):889-96.
5. Cauchemez S, Valleron AJ, Boëlle PY, Flahault A, Ferguson NM. Estimating the impact of school closure on influenza transmission from sentinel data. Nature. 2008;452(7188):750-4.
6. Health Protection Agency. HPA advice on actions to be taken in a school in the event of a probable or confirmed case of "swine flu" being identified in a school pupil. HPA; 2009. [Available on request].
7. Roche Products Limited. Summary of product characteristics for Tamiflu. The electronic Medicines Compendium (eMC). Hertfordshire: 2009. Available from: http://emc.medicines.org.uk/document.aspx?documentId=10446
8. US Food and Drug Administration (FDA). FDA MedWatch: 2008 Safety Alerts for Human Medical Products (Drugs, Biologics, Medical Devices, Special Nutritionals, and Cosmetics): Tamiflu (oseltamivir phosphate) [3 April 2008]; Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm095044.htm